Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

128.40 +0.20 (+0.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Unusual volume stocks are being observed in Monday's session.
Unusual volume stocks in Monday's session 
Via Chartmill
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
Via Benzinga
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates. 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Analyst Expectations For Blueprint Medicines's Future
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
This ASML Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
This Salesforce Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Market Monitor News June 03 (Cleveland-Cliffs, Blueprint Medicines UP - First Solar DOWN)
Wall Street Climbs Despite Trade Tensions: Steel Stocks Shine, Apple Impresses 
Via Chartmill
Blueprint Medicines Stock Lands Several Downgrades After Sanofi’s Buyout Deal, But Retail Bulls Keep The Faith
Analysts revised price targets near the deal’s $129-per-share valuation. 
Via Stocktwits
Topics Government
Exposures Political
Blueprint Medicines Earnings Preview
Via Benzinga
13 Analysts Assess Blueprint Medicines: What You Need To Know
Via Benzinga
Breaking Down Blueprint Medicines: 10 Analysts Share Their Views
Via Benzinga
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Which stocks are gapping on Monday?
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
This Union Pacific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Earnings Scheduled For February 13, 2025
Via Benzinga
Analyst Expectations For Blueprint Medicines's Future
Via Benzinga
Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies
Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35. 
Via Stocktwits
These stocks that are showing activity before the opening bell on Monday.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib. 
Via Benzinga
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
Via Benzinga
US Stocks Likely To Open Lower After A Solid May: 'TACO' Trade And 'Run It Hot' Optimism 'Are Consensus At This Point,' Says Expert
U.S. stock futures fell on Monday after a mixed close on Friday. Futures of major benchmark indices were trading lower in premarket. 
Via Benzinga
Campbell's, SAIC And 3 Stocks To Watch Heading Into Monday
Via Benzinga
What Analysts Are Saying About Blueprint Medicines Stock
Via Benzinga
Breaking Down Blueprint Medicines: 14 Analysts Share Their Views
Via Benzinga
The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts
Via Benzinga
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.